Progress towards zero environmental impact

Being respected for adding value to society

Ensure distinct core capabilities and evolve culture

Further raise the innovation-bar for diabetes treatment

Develop a leading portfolio of superior treatment solutions for obesity

Strengthen and progress the Rare disease pipeline 

Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD

Strengthen Diabetes leadership - aim at global value market share of more than 1/3

More than 25 billion DKK in Obesity sales by 2025

Secure a sustained growth outlook for Rare disease

Deliver solid sales and operating profit growth:

  • Deliver 6-10% sales growth in International Operations
  • Transform 70% of sales in the USA1

Drive operational efficiencies across the value chain to enable investments in future growth assets

Deliver free cash flow to enable attractive capital allocation to shareholders

Investors

Share price

{{priceData.date}} {{priceData.time}}

{{priceData.currentPrice}} {{priceData.currency}}
Go to stock watch {{priceData.change}} {{priceData.currency}}

Annual Report

Cover page of the Novo Nordisk Annual Report 2021

Annual Report 2021

Download Annual Report